Posted by Michael Wonder on 23 Oct 2025
Dupixent (dupilumab injection) approved in Canada for adults with inadequately controlled chronic obstructive pulmonary disease
22 October 2025 - Health Canada has approved Dupixent (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease characterised by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta 2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
This approval was based on findings from two clinical studies conducted in adult patients already receiving maximal standard of care inhaled therapy. The BOREAS and NOTUS studies showed a 30% and 34% reduction in moderate or severe exacerbations over one year.
